Artificial Intelligence-based Analysis of Retinal Fluid Volume Dynamics in Neovascular Age-related Macular Degeneration and Association with Vision and Atrophy

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2024 Oct 15

PMID 39406933

Authors

Siqing Yu

Ian Lloyd Jones

Andreas Maunz

Isabel Bachmeier

Thomas Albrecht

Andreas Ebneter

Martin Gliem

Giovanni Staurenghi

Srinivas R Sadda

Usha Chakravarty

Sascha Fauser

Affiliations

Soon will be listed here.

Abstract

Background/objectives: To characterise morphological changes in neovascular age-related macular degeneration (nAMD) during anti-angiogenic therapy and explore relationships with best-corrected visual acuity (BCVA) and development of macular atrophy (MA).

Subjects/methods: Post-hoc analysis of the phase III HARBOR trial. SD-OCT scans from 1097 treatment-naïve nAMD eyes were analysed. Volumes of intraretinal cystoid fluid (ICF), subretinal hyperreflective material (SHRM), subretinal fluid (SRF), pigment epithelial detachment (PED) and cyst-free retinal volume (CFRV) were measured by deep-learning model. Volumes were analysed by treatment regimen, macular neovascularisation (MNV) subtypes and topographic location. Associations of volumetric features with BCVA and MA development were quantified at month 12/24.

Results: Differences in feature volume changes by treatment regimens and MNV subtypes were observed. Each additional 100 nanolitre unit (AHNU) of residual ICF, SHRM and CFRV at month 1 in the fovea was associated with deficits of 10.3, 7.3 and 12.2 letters at month 12. Baseline AHNUs of ICF, CFRV and PED were associated with increased odds of MA development at month 12 by 10%, 4% and 3%. While that of SRF was associated with a decrease in odds of 5%. Associations at month 24 were similar to those at month 12.

Conclusion: Eyes with different MNV subtypes showed distinct trajectories of feature volume response to treatment. Higher baseline volumes of ICF or PED and lower baseline volume of SRF were associated with higher likelihoods of MA development over 24 months. Residual intraretinal fluid, including ICF and CFRV, along with SHRM were predictors of poor visual outcomes.

References

Schmidt-Erfurth U, Waldstein S . A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2015; 50:1-24. DOI: 10.1016/j.preteyeres.2015.07.007. View

Zarbin M, Hill L, Maunz A, Gliem M, Stoilov I . Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. Br J Ophthalmol. 2021; 106(11):1561-1566. PMC: 9606534. DOI: 10.1136/bjophthalmol-2020-318688. View

Riedl S, Vogl W, Waldstein S, Schmidt-Erfurth U, Bogunovic H . Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial. Ophthalmol Retina. 2021; 6(4):291-297. DOI: 10.1016/j.oret.2021.12.007. View

Busbee B, Ho A, Brown D, Heier J, Suner I, Li Z . Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5):1046-56. DOI: 10.1016/j.ophtha.2012.10.014. View

Schmidt-Erfurth U, Vogl W, Jampol L, Bogunovic H . Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020; 127(9):1211-1219. DOI: 10.1016/j.ophtha.2020.03.010. View

Spaide R, Jaffe G, Sarraf D, Freund K, Sadda S, Staurenghi G . Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2019; 127(5):616-636. PMC: 11559632. DOI: 10.1016/j.ophtha.2019.11.004. View

Staurenghi G, Cozzi M, Sadda S, Hill L, Gune S . Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2022; 7(4):300-306. DOI: 10.1016/j.oret.2022.11.002. View

Casalino G, Stevenson M, Bandello F, Chakravarthy U . Tomographic Biomarkers Predicting Progression to Fibrosis in Treated Neovascular Age-Related Macular Degeneration: A Multimodal Imaging Study. Ophthalmol Retina. 2019; 2(5):451-461. DOI: 10.1016/j.oret.2017.08.019. View

Guymer R, Markey C, McAllister I, Gillies M, Hunyor A, Arnold J . Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2018; 126(5):723-734. DOI: 10.1016/j.ophtha.2018.11.025. View

10.

Abdelfattah N, Al-Sheikh M, Pitetta S, Mousa A, Sadda S, Wykoff C . Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2016; 124(2):215-223. DOI: 10.1016/j.ophtha.2016.10.002. View

11.

Schlegl T, Waldstein S, Bogunovic H, Endstrasser F, Sadeghipour A, Philip A . Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning. Ophthalmology. 2017; 125(4):549-558. DOI: 10.1016/j.ophtha.2017.10.031. View

12.

Ho A, Busbee B, Regillo C, Wieland M, Van Everen S, Li Z . Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014; 121(11):2181-92. DOI: 10.1016/j.ophtha.2014.05.009. View

13.

Grunwald J, Daniel E, Huang J, Ying G, Maguire M, Toth C . Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013; 121(1):150-161. PMC: 3892560. DOI: 10.1016/j.ophtha.2013.08.015. View

14.

Sadda S, Abdelfattah N, Lei J, Shi Y, Marion K, Morgenthien E . Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020; 127(10):1360-1370. DOI: 10.1016/j.ophtha.2020.03.031. View

15.

Yu S, Bachmeier I, Hernandez-Sanchez J, Armendariz B, Ebneter A, Pauleikhoff D . Hyperreflective Material Boundary Remodeling in Neovascular Age-Related Macular Degeneration: A Post Hoc Analysis of the AVENUE Trial. Ophthalmol Retina. 2023; 7(11):990-998. DOI: 10.1016/j.oret.2023.06.024. View

16.

Bloch S, Lund-Andersen H, Sander B, Larsen M . Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Am J Ophthalmol. 2013; 156(1):116-124.e1. DOI: 10.1016/j.ajo.2013.02.012. View

17.

Roberts P, Zotter S, Montuoro A, Pircher M, Baumann B, Ritter M . Identification and Quantification of the Angiofibrotic Switch in Neovascular AMD. Invest Ophthalmol Vis Sci. 2019; 60(1):304-311. DOI: 10.1167/iovs.18-25189. View

18.

Maunz A, Benmansour F, Li Y, Albrecht T, Zhang Y, Arcadu F . Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography. J Pers Med. 2021; 11(6). PMC: 8227725. DOI: 10.3390/jpm11060524. View

19.

Kumar J, Stinnett S, Han J, Jaffe G . CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2019; 40(5):845-856. DOI: 10.1097/IAE.0000000000002552. View

20.

Reiter G, Grechenig C, Vogl W, Guymer R, Arnold J, Bogunovic H . ANALYSIS OF FLUID VOLUME AND ITS IMPACT ON VISUAL ACUITY IN THE FLUID STUDY AS QUANTIFIED WITH DEEP LEARNING. Retina. 2020; 41(6):1318-1328. DOI: 10.1097/IAE.0000000000003023. View